Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|November 24, 2020

v

Episodes in this series

EP. 1 v

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

The Right Way to Avoid Malpractice Lawsuits

ByWilliam H. Reid, MD, MPH,Skip Simpson, JD

September 30th 2020

Looking to the Future and Improving Patient Care

ByMichelle Riba, MD, MS, DFAPA, FAPM,Luigi Grassi, MD

August 31st 2020

Case-Based Clinical Approaches for Clinicians

ByLawrence E. Kaplan, DO

August 31st 2020

Finding Meaning in the Face of Suffering

ByWendy G. Lichtenthal, PhD,Kailey E. Roberts, PhD,Hayley Pessin, PhD,Allison Applebaum, PhD,William Breitbart, MD

August 31st 2020

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Debunking the Top 10 Misleading Claims About Antidepressants

New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

State Funding for Suicide Prevention and Crisis Services Climbs Sharply From 2021 to 2026

Adult ADHD Prevalence and the Diversity of Symptoms